Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06709014 · ClinicalTrials.gov registry record · Phase 3
A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD
A Phase 3 study of Early Alzheimer's Disease, sponsored by Annovis Bio.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 760
- Enrollment target
- 20
- Study locations
NCT06709014 is a Phase 3 study of Early Alzheimer's Disease that is actively recruiting participants, run by Annovis Bio. The registered enrollment target is 760 participants, below the 993-participant average among 7 other Early Alzheimer's Disease trials with a reported enrollment target (23% lower). The trial reports 20 study locations across 5 states.
The verdict
NCT06709014, a Phase 3 study of Early Alzheimer's Disease, is actively recruiting participants, sponsored by Annovis Bio.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 760 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this clinical trial is to learn if buntanetap/Posiphen works to treat early Alzheimer's disease in adults aged 55-85. It will also learn about the safety of buntanetap/Posiphen. The main questions it aims to answer are: * Does buntanetap/Posiphen improve cognition as measured by ADAS-Cog13? * Does buntanetap/Posiphen improve function as measured by ADCS-iADL? * What medical issues do participants have, if any, when taking buntanetap/Posiphen? Researchers will compare buntanetap/Posiphen to a placebo (a look-alike substance that contains no drug) to see if buntanetap/Posiphen works to treat early Alzheimer's disease. Participants will: * Take buntanetap/Posiphen or a placebo every day for 18 months * Visit the clinic periodically for checkups, tests, and questionnaires (screening visits, enrollment, month 1, month 3, month 6, month 9, month 12, month 15, month 18), including a volumetric MRI at month 6 and month 18 * Complete pre- and post-clinic visit phone calls
Conditions Studied
Interventions
- DRUG Placebo
- DRUG buntanetap/posiphen
Study Locations (20)
California
- Advanced Research Center - Anaheim
- Hope Clinical Research - Canoga Park
- Eximia Clinical Research - Encino
- Sun Valley Research - Imperial
- Mary S. Easton Center for Alzheimer's Research and Care, UCLA - Los Angeles
- UC Davis Alzheimer's Disease Research Center - Sacramento
- The Neuron Clinic - San Marcos
Florida
- Visionary Investigators Network - Aventura
- SFM Clinical Research - Boca Raton
- K2 Medical Research - Clermont
- K2 Medical Research Daytona - Daytona Beach
- Neuropsychiatric Research Center - Fort Myers
- Velocity Clinical - Hallandale
- Jacksonville Center for Clinical Research - Jacksonville
Arizona
- MD First Research - Chandler
- Xenoscience - Phoenix
- Clinical Endpoints - Scottsdale
Colorado
- Mountain Neurological Center - Basalt
- CenExel Rocky Mountain - Englewood
Connecticut
- Research Center for Clinical Trials - Norwalk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 760 participants |
| Start Date | 2025-02-04 |
| Est. Completion | 2028-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06709014
The ClinicalTrials.gov registry entry for NCT06709014 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 760 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 993-participant average among 7 other Early Alzheimer's Disease trials with a reported enrollment target (23% lower). The listed sponsor is Annovis Bio, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Early Alzheimer's Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06709014 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT06709014 about?
NCT06709014 is a clinical study titled "A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD". The goal of this clinical trial is to learn if buntanetap/Posiphen works to treat early Alzheimer's disease in adults aged 55-85. It will also learn about the safety of buntanetap/Posiphen. The main questions it aims to answer are: * Does buntanetap/Posiphen improve cognition as measured by ADAS-Co...
What is the current status of trial NCT06709014?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 760 participants. The study started on 2025-02-04. Estimated completion is 2028-06.
What conditions does trial NCT06709014 study?
This clinical trial studies the following conditions: Early Alzheimer's Disease.
What interventions are being tested in trial NCT06709014?
The interventions under investigation include: Placebo (DRUG), buntanetap/posiphen (DRUG).
Who is sponsoring clinical trial NCT06709014?
This trial is sponsored by Annovis Bio, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06709014 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Early Alzheimer's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
ACTIVE NOT RECRUITING · Phase 3
-
Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)
ACTIVE NOT RECRUITING · Phase 3
-
An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects
COMPLETED · Phase 3
-
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.